Omeros Announces $16.2 Million Registered Direct Offering of Common Stock

  Omeros Announces $16.2 Million Registered Direct Offering of Common Stock

PR Newswire

SEATTLE, May 9, 2013

SEATTLE, May 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today
announced that it has agreed to sell 3,903,004 shares of its common stock at a
price of $4.14 per share, a two percent premium over the closing price on May
8, 2013, for gross proceeds of $16.2 million. The shares were offered and are
expected to be sold to RA Capital Management and other investors in a
registered direct offering conducted without an underwriter or placement
agent. The net proceeds from the offering, after deducting estimated offering
expenses, will be approximately $16.1 million. The offering is expected to
close on or about May 14, 2013.

Omeros intends to use the net proceeds of the offering for general corporate
purposes, including expenses related to the potential commercialization of
OMS302 for intraocular lens replacement, as well as for research and
development expenses, such as funding planned clinical trials for its
OMS103HP, PDE10, MASP-2 and PDE7 programs. The net proceeds may also be used
to fund pre-clinical studies, capital expenditures, working capital and to
otherwise advance Omeros' potential products towards commercialization.

The securities were offered by means of a prospectus supplement dated May 9,
2013 and accompanying prospectus dated October 18, 2010, forming a part of the
Company's effective shelf registration statement (File No. 333-169856). Omeros
has filed a registration statement (including a prospectus) with the
Securities and Exchange Commission, or SEC, for the offering to which this
communication relates. Before you invest, you should read the prospectus in
that registration statement and other documents Omeros has filed with the SEC
for more complete information about Omeros and this offering. You may get
these documents for free by visiting EDGAR on the SEC web site at
Alternatively, Omeros will arrange to send you the prospectus if you request
it by calling Omeros at 206-676-5000.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products targeting inflammation, coagulopathies
and disorders of the central nervous system. The Company's most clinically
advanced product candidates, OMS302 for lens replacement surgery and OMS103HP
for arthroscopy, are derived from its proprietary PharmacoSurgery‚ĄĘ platform
designed to improve clinical outcomes of patients undergoing a wide range of
surgical and medical procedures. Omeros has five clinical development
programs. Omeros may also have the near-term capability, through its GPCR
program, to add a large number of new drug targets and their corresponding
compounds to the market. Behind its clinical candidates and GPCR platform,
Omeros is building a diverse pipeline of protein and small-molecule
preclinical programs targeting inflammation, coagulopathies and central
nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995, which are subject to the
"safe harbor" created by those sections. These statements include, but are not
limited to, statements regarding Omeros' expectations regarding the offering
announced today and the use of proceeds thereof. Forward-looking statements
are based on management's beliefs and assumptions and on information available
to management only as of the date of this press release. Omeros' actual
results could differ materially from those anticipated in these
forward-looking statements for many reasons, including, without limitation,
the risks, uncertainties and other factors described under the heading "Risk
Factors" in the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on May 9, 2013. Given these risks,
uncertainties and other factors, you should not place undue reliance on these
forward-looking statements, and the Company assumes no obligation to update
these forward-looking statements publicly, even if new information becomes
available in the future.

Jennifer Cook Williams

SOURCE Omeros Corporation
Press spacebar to pause and continue. Press esc to stop.